To explore the domestic factors affecting the implementation of pharmacogenomics (PGx) and its future prospects in China, we carried out a questionnaire-based survey on PGx applications and testing. The survey was designed on the widely used online platform “Wenjuanxing” (www.wjx.cn) and distributed via the social media app WeChat. Among the 422 respondents, 27.7% were physicians, 31.3% were pharmacists, and 41.0% were researchers. Less than half of the physicians recognized the importance of PGx in drug therapy, whereas over half of the pharmacists and researchers acknowledged its significance. Only 38.5% of physicians, 40.9% of pharmacists, and 55.5% of researchers agreed that PGx testing could help reduce patients’ economic burden. Nonetheless, the majority supported the effective integration of PGx into clinical practice. Key barriers to implementation included the absence of sector-specific standards, limited clinical research, and insufficient guidelines. Among drugs linked to PGx assays, warfarin and clopidogrel were the most frequently cited. Despite rapid advancements in PGx research in mainland China in recent years, its clinical application remains limited.
